The Meningitis Research Foundation said on Wednesday that it will begin research on how to assess potential Group B Streptococcal vaccines against meningitis and the impact of introducing vaccines to pregnant women.
The study will be led by Caroline Trotter at the University of Cambridge. It will construct a model of how the meningitis spreads and examine the disease's impact based on the most current information available.
Results from the MRF's neonatal meningitis study completed in 2013 will be included, as well as new information gathered from following up with study participants.
MRF said developing a trend model now will help identify information gaps and ensure evidence that is needed to make decisions about new GBS vaccines will be available. The model will include information from current GBS trials and others that will enter clinical trials.
In the United Kingdom, vaccines must be shown to be cost-effective before they are recommended for use.
"Understanding the impact of GBS vaccines and the costs related to their introduction is important for policy makers in designing future strategies against GBS infection, and this work aims to fill this knowledge gap," Kyriaki Giorgakoudi, a research team member, said.
GBS is the leading cause of bacterial meningitis in newborn babies the U.K.